SNPMiner Trials (Home Page)
Report for Clinical Trial NCT02140333
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
The purpose of this study is to determine whether 100mg erlotinib had similar effect compared
with 150mg erlotinib in NSCLC patients with EGFR mutation in China.
NCT02140333 NSCLC EGFR Mutation
1 Interventions
Name: Erlotinib
Description: 100mg vs. 150mg
Type: Drug
Group Labels: 2 Erlotinib 100mg Erlotinib 150mg
Primary Outcomes
Measure: Progression free survival Time: 2 years after the initial dose
Secondary Outcomes
Measure: The objective response rate Time: Patients will be followed for an expected average of 6 months
Other Outcomes
Measure: Overall survival Time: 3 year after the initial dose
Measure: Adverse events Time: 1 year
Purpose: Treatment
Allocation: Randomized
Parallel Assignment
There is one SNP
SNPs
Inclusion Criteria:
1. Histological diagnosis of NSCLC with phase IIIB or IV disease;
2. Sensitive mutation EGFR gene (18, 19 del, 21 L858R gene mutation) (mutation detection
methods:ARMS-PCR, sequence method)
3. Never received anti-tumor therapies for the advanced stage;
4. Never used EGFR inhibitors;
5. Measurable disease by RECIST criteria;
6. --- L858R ---
HPO Nodes